Familial Mediterranean Fever - Dietary Habits and Symptom Management

A Case-Control Study Investigating the Association Between Dietary Components and Familial Mediterranean Fever (FMF) Symptoms: A Novel Approach to Personalized Nutrition and Therapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241022008

Enrollment

150

Registered

2024-10-22

Start date

2021-08-18

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Mediterranean Fever Infections and Infestations Nutritional Metabolic Endocrine Abdominal pain Chest pain Arthritis Familial Mediterranean Fever Adolescent nutrition science Allowance, recommended dietary Personalized Medicine Inflammation Gene Expression Biochemical genetic Nutrition assessment

Interventions

This study aims to investigate the association between dietary components and FMF symptoms, with the ultimate goal of developing a personalized nutrition approach for FMF management. The intervention

Experimental Dietary Supplement

Personalized Nutrition Approach

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. A diagnosis of Familial Mediterranean Fever (FMF) according to the Tel-Hashomer criteria and experiencing active disease at the time of enrollment, 2. Age above 18 years, 3. Willingness to provide detailed dietary information.

Exclusion criteria

Exclusion criteria: 1. Presence of comorbidities that could affect dietary habits, such as gastrointestinal disorders or food allergies, 2. Pregnancy or lactation, 3. History of smoking, alcoholism, or chronic diseases (e.g., diabetes, hypertension, or cardiovascular disease), 4. Current participation in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Symptom severity of Familial Mediterranean Fever (FMF) At 6 months after the start of the intervention FMF Symptom Severity Score using a validated questionnaire (e.g., FMF Symptom Severity Questionnaire)	—

Secondary

Measure	Time frame
Quality of life of patients with Familial Mediterranean Fever (FMF) At 12 months after the start of the intervention Quality of Life Questionnaire (e.g., SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS),Inflammatory biomarkers in FMF patients The secondary outcome will be measured at baseline, 3 months, 6 months, and 12 months after the intervention. Level of C-Reactive Protein, Erythrocyte Sedimentation Rate (ESR), and Interleukin-1 beta in blood samples.	—

Measure

Time frame

Quality of life of patients with Familial Mediterranean Fever (FMF) At 12 months after the start of the intervention Quality of Life Questionnaire (e.g., SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS),Inflammatory biomarkers in FMF patients The secondary outcome will be measured at baseline, 3 months, 6 months, and 12 months after the intervention. Level of C-Reactive Protein, Erythrocyte Sedimentation Rate (ESR), and Interleukin-1 beta in blood samples.

—

Countries

Syrian Arab Republic

Contacts

Public ContactNinar AlJerf

Al-Basil High School for Superiors, Jaramana, F8QP+2W9, Damascus, Syrian Arab Republic

Ninar.Superiors@outlook.sa00963112718704

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026